{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:36:31Z","timestamp":1793223391123,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["R01 MH054907 (D.R.B.)"],"award-info":[{"award-number":["R01 MH054907 (D.R.B.)"]}]},{"name":"National Institute of Health","award":["R01 AI162221 (G.Q.L.)"],"award-info":[{"award-number":["R01 AI162221 (G.Q.L.)"]}]},{"name":"National Institute of Health","award":["R21 AI150398 (G.Q.L.)"],"award-info":[{"award-number":["R21 AI150398 (G.Q.L.)"]}]},{"name":"National Institute of Health","award":["P30 AI027763 (J.N.M.)"],"award-info":[{"award-number":["P30 AI027763 (J.N.M.)"]}]},{"name":"National Institute of Health","award":["K23 AI143470 (S"],"award-info":[{"award-number":["K23 AI143470 (S"]}]},{"name":"National Institute of Health","award":[".M.)]"],"award-info":[{"award-number":[".M.)]"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechanism and lack of cross-resistance with other antiretroviral classes make lenacapavir a significant addition to HIV therapy. The clinical trials CALIBRATE and CAPELLA have demonstrated high viral suppression rates in both ART-naive individuals and individuals with MDR HIV-1. Lenacapavir-associated resistance mutations, such as M66I and Q67H, rarely seen as natural polymorphisms in lenacapavir-naive populations, are predominantly studied in subtype B HIV-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our study aimed to investigate the prevalence of lenacapavir resistance-associated mutations in HIV-1 subtypes A1 and D in a cohort of individuals living with HIV-1 from southwestern Uganda.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Utilizing plasma samples from ART-naive adults living in Uganda, HIV-1 Gag p24 (capsid) sequences were analysed for lenacapavir resistance mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 546 lenacapavir-naive participants, no major lenacapavir resistance-associated mutations were found. Minor mutations were present in 1.6% of participants, with T107A being the most common. Longitudinal data indicated the persistence of T107A for at least 3\u2005years post-ART initiation in one participant. Phylogenetic analysis indicated individuals carrying T107A were found independently in distinct locations within the tree, suggesting that T107A might have arisen from multiple distinct base substitution events. Shannon entropy analysis showed high variability in certain capsid sites, but none overlapped with known lenacapavir resistance sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings suggest a low prevalence of naturally occurring lenacapavir resistance mutations in Uganda, supporting lenacapavir\u2019s potential efficacy in this region.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf018","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:53:36Z","timestamp":1738216416000},"page":"955-961","source":"Crossref","is-referenced-by-count":12,"title":["Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-5732","authenticated-orcid":false,"given":"Daniel","family":"Omoding","sequence":"first","affiliation":[{"name":"Department of Community Health, Mbarara University of Science and Technology , Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Musinguzi","sequence":"additional","affiliation":[{"name":"Department of Community Health, Mbarara University of Science and Technology , Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Yap","family":"Boum","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Bangui , Bangui ,","place":["Central African Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Muzoora","sequence":"additional","affiliation":[{"name":"Department of Community Health, Mbarara University of Science and Technology , Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Kigozi","sequence":"additional","affiliation":[{"name":"Department of Community Health, Mbarara University of Science and Technology , Mbarara ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Bangsberg","sequence":"additional","affiliation":[{"name":"College of Health Sciences, VinUniversity , Hanoi ,","place":["Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E","family":"Haberer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Siedner","sequence":"additional","affiliation":[{"name":"Department of Community Health, Mbarara University of Science and Technology , Mbarara ,","place":["Uganda"]},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M","family":"McCluskey","sequence":"additional","affiliation":[{"name":"Department of Community Health, Mbarara University of Science and Technology , Mbarara ,","place":["Uganda"]},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-886X","authenticated-orcid":false,"given":"Guinevere Q","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025040208382523100_dkaf018-B1","author":"Gilead"},{"key":"2025040208382523100_dkaf018-B2","author":"FDA"},{"key":"2025040208382523100_dkaf018-B3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"2025040208382523100_dkaf018-B4","author":"Gilead Sciences, Inc"},{"key":"2025040208382523100_dkaf018-B5","doi-asserted-by":"publisher","first-page":"e02057-20","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208382523100_dkaf018-B6","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"2025040208382523100_dkaf018-B7","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2025040208382523100_dkaf018-B8","author":"Yant"},{"key":"2025040208382523100_dkaf018-B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2025040208382523100_dkaf018-B10","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/jac\/dkaa060","article-title":"Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients","volume":"75","author":"Marcelin","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025040208382523100_dkaf018-B11","doi-asserted-by":"publisher","first-page":"854974","DOI":"10.3389\/fmicb.2022.854974","article-title":"HIV capsid protein genetic diversity across HIV-1 variants and impact on new capsid-inhibitor lenacapavir","volume":"13","author":"Troyano-Hern\u00e1ez","year":"2022","journal-title":"Front Microbiol"},{"key":"2025040208382523100_dkaf018-B12","author":"UNICEF"},{"key":"2025040208382523100_dkaf018-B13","author":"Hansen"},{"key":"2025040208382523100_dkaf018-B14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/QAI.0000000000001487","article-title":"Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?","volume":"76","author":"Lee","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025040208382523100_dkaf018-B15","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1097\/QAD.0000000000001619","article-title":"Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches","volume":"31","author":"Lee","year":"2017","journal-title":"AIDS"},{"key":"2025040208382523100_dkaf018-B16","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2025040208382523100_dkaf018-B17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0022-2836(82)90398-9","article-title":"An improved algorithm for matching biological sequences","volume":"162","author":"Gotoh","year":"1982","journal-title":"J Mol Biol"},{"key":"2025040208382523100_dkaf018-B18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/sysbio\/syq010","article-title":"New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0","volume":"59","author":"Guindon","year":"2010","journal-title":"Syst Biol"},{"key":"2025040208382523100_dkaf018-B19","author":"HIVdb"},{"key":"2025040208382523100_dkaf018-B20","doi-asserted-by":"publisher","first-page":"e01502-18","DOI":"10.1128\/jvi.01502-18","article-title":"Genotypic and mechanistic characterization of subtype-specific HIV adaptation to host cellular immunity","volume":"93","author":"Kinloch","year":"2018","journal-title":"J Virol"},{"key":"2025040208382523100_dkaf018-B21","first-page":"559","article-title":"Special contribution; 2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"key":"2025040208382523100_dkaf018-B22","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance analyses in highly treatment-experienced people with HIV treated with the novel capsid HIV inhibitor lenacapavir","volume":"226","author":"Margot","year":"2022","journal-title":"J Infect Dis"},{"key":"2025040208382523100_dkaf018-B23","author":"Ogbuagu"},{"key":"2025040208382523100_dkaf018-B24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2025040208382523100_dkaf018-B25","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis"},{"key":"2025040208382523100_dkaf018-B26","author":"Stanford HIVdb version 9.6"},{"key":"2025040208382523100_dkaf018-B27","doi-asserted-by":"publisher","first-page":"13596535231220754","DOI":"10.1177\/13596535231220754","article-title":"Cross-resistance to entry inhibitors and lenacapavir resistance through week 52 in study CAPELLA","volume":"28","author":"Margot","year":"2023","journal-title":"Antivir Ther"},{"key":"2025040208382523100_dkaf018-B28","author":"Margot"},{"key":"2025040208382523100_dkaf018-B29","author":"Stanford HIVdb version 9.7"},{"key":"2025040208382523100_dkaf018-B30","author":"Stanford HIVdb version 9.6"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/955\/61686388\/dkaf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/955\/61686388\/dkaf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T09:25:12Z","timestamp":1743585912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/955\/7989498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf018","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,30]]}}}